Featured Article
PCSK9 Inhibition: Benefits Outweigh Risks in Patients With Diabetes
Statin therapy is the first line of defense against high LDL-C and the risk for atherosclerotic cardiovascular disease, the leading cause of morbidity and mortality in individuals with diabetes.
Latest Features
PCSK9 Inhibition: Benefits Outweigh Risks in Patients With Diabetes
Statin therapy is the first line of defense against high LDL-C and the risk for atherosclerotic cardiovascular disease, the leading cause of morbidity and mortality in individuals with diabetes.
Nutraceuticals May Benefit Patients Who Are Statin Intolerant
Nutraceuticals may offer a solution to patients who cannot tolerate statins because of severe muscle pain.
Breathing New Life Into COPD and Asthma Therapy With Statins
Statins have anti-inflammatory and anti-oxidative effects, which could reduce exacerbations of both asthma and chronic obstructive pulmonary disease.
FOURIER Trial Data Questions: Are PCSK9 Inhibitors The Right Choice?
Results of the FOURIER trial, presented at the 2017 ACC Scientific Sessions, raise questions about the efficacy of PCSK9 inhibitors as long-term therapy for patients with atherosclerotic CVD.
PCSK9 Inhibitor Alirocumab Associated With 75% Reduction in Apheresis
Among patients with heterozygous familial hypercholesterolemia, alirocumab was associated with a 75% reduction in lipoprotein apheresis compared with placebo.
Statins Limit Vaccine Efficacy of Influenza Strain
Statin use modified vaccine effectiveness and influenza risk for A(H3N2) infection but not for A(H1N1).
Higher Vitamin D Levels May Related to Higher Total Cholesterol, HDL-C
Vitamin D may influence cardiovascular disease risk via its effect on lipid levels.
Considering Cardiovascular Risks of Antidiabetic Drugs
A review of current antidiabetic drug treatments available and their individual cardiovascular risk profiles.
PCSK9 Inhibitors: Breakthrough in LDL-C Reduction, But Comes at a Cost
PCSK9 inhibitors may offer hope to patients with familial hypercholesterolemia who cannot tolerate or achieve goal LDL-C levels with statins.
LATEST NEWS
Adherence and Intensity of Lipid-Lowering Therapy Influence CV Risk
Adherent patients receiving high-intensity statin and/or ezetimibe therapy have the lowest cardiovascular risk.
Should Guidelines Use Higher Risk Thresholds When Recommending Statins for Primary CVD Prevention?
Guidelines should incorporate using higher 10-year risk thresholds when recommending statins for the purpose of primary CVD prevention.
AHA Scientific Statement: Low Risk of Side Effects With Statins
Statins are associated with a low risk for side effects, according to a scientific statement from the American Heart Association.
Long-Term Clinical Outcomes of Statin Therapy Post-PCI in Absence of Dyslipidemia
A positive relationship was found between statin use and MACE-free survival after AMI regardless of the presence or absence of dyslipidemia.
Statin Use May Improve Bone Microstructure in Women With Osteoporosis
Statin use is associated with better cortical bone characteristics in older women with osteoporosis, but results are dependent upon the potency of the statins.
Coronary Artery Calcium Associated With ASCVD Events in Familial Hypercholesterolemia
CAC was found to be independently associated with ASCVD events in familiar hypercholesterolemia treated with standard lipid lowering therapy.
Elevated Triglyceride Levels Affect Glycemic Control in Type 2 Diabetes
Reducing triglyceride levels in patients with type 2 diabetes may help them attain more optimal glycemic control.
Linear Association Between Plasma Lipoprotein(a) and Calcific Aortic Valve Stenosis Progression
Lipoprotein(a) levels should be measured in mild to moderate calcific aortic valve stenosis to improve patient risk stratification.
Hyperlipidemia Screening Rates Low Among Patients With Rheumatoid Arthritis
Primary lipid screening rates were suboptimal among patients with rheumatoid arthritis.
ACC Releases Consensus Decision Pathway for CVD Risk Reduction in T2D and ASCVD
The American College of Cardiology published an expert consensus statement regarding decision considerations for novel cardiovascular risk reduction therapies in patients with type 2 diabetes and atherosclerotic cardiovascular disease.
The Cardiology Advisor Articles
- Should Guidelines Use Higher Risk Thresholds When Recommending Statins for Primary CVD Prevention?
- Ezetimibe Plus Statins Modestly Reduce Cardiovascular Disease Event Risk
- ACC, AHA Publish Appropriate Use Criteria Guidelines for Peripheral Artery Intervention
- FDA: E-Liquids Found to Contain Undeclared Sildenafil and Tadalafil
- Ultrasound-Based Visualization of Silent Atherosclerosis May Improve Medication Adherence
- ACC Releases Consensus Decision Pathway for CVD Risk Reduction in T2D and ASCVD
- Childhood Behavioral Interventions May Promote Adult Cardiovascular Health
- US Medical Schools Increase in Diversity After Implementation of Accreditation Standards
- Botox Injections Explored to Reduce Postop AF in Cardiac Surgery
- AHA Scientific Statement: Low Risk of Side Effects With Statins
- Do More Aggressive Periprocedural Antibiotic Regimens Reduce Risk of Device-Related Infections?
- Adherence and Intensity of Lipid-Lowering Therapy Influence CV Risk
- Challenges in Weighing Costs, Therapeutic Benefits of Expensive Pharmaceuticals
- Sustained Systolic Blood Pressure Reductions With Barbershop Intervention
- Stethoscopes in ICU Show High Levels of Bacterial Contamination